Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Hodgkin's Disease

Abstract

s / Biol Blood Marrow Transplant 21 (2015) S185eS205 S197 conditioning and allogeneic hematopoietic stem cell transplantation (AlloSCT) from EBV positive HLA matched sibling or unrelated adult donors. Methods: EBV positive patients with poor-risk HL will receive a reduced intensity conditioning regimen followed by an allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with up to three doses of post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions (Fig 1A) as previously described.(Bollard et al, Blood 2007) Results: To date, our first patient has successfully completed therapy e a 20yr-old male with EBV+ relapsed/refractory Hodgkin Lymphoma who received his donor EBV-CTL infusion approximately 60 days post AlloSCT from an EBV+ 10/10 MUD donor without adverse effect or complication. Conclusions: The development of this multicenter LCTC consists of 9 outstanding multidisciplinary academic centers (Fig 1B) that comprise expertise in CAYA clinical and translational lymphoma research, lymphoma biology and biopathology, stem and cell therapy, targeted cell therapy manufacturing (GMP), biostatistics and bioinformatics, and expertise in state and federal regulatory compliance. This consortium is poised to rapidly translate targeted cell therapy in CAYA with highor poor-risk lymphomas. Further results from this trial will provide critical information to develop future randomized trials investigating the use of donor derived LMP-CTLs.